Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Announces Preliminary Revenue Range for the First Quarter of 2021 Announces Preliminary Revenue Range for the First Quarter of 2021

Shockwave Provides Update on U.S. Launch of Coronary IVL System

FinVolution Group

Jumia

Buying these stocks is a smart way to make that stimulus check work for your future.

These 3 Disruptive Stocks Could Easily Double Your $1,400 Stimulus Check

The medical-device maker needs to keep its foot on the revenue gas.

Shockwave Medical Has Captured Just a Fraction of Its $6 Billion Market Potential

Shockwave Medical Continues to Execute on Its Growth Plans

Tesla

Twilio

Hint: Focus on the business, not the stock.

How to Sleep Soundly When One of Your Big Stocks Has a Really Bad Day

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q4 2020 Results - Earnings Call Transcript

Shockwave Medical (SWAV) delivered earnings and revenue surprises of -12.20% and 11.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Reports Q4 Loss, Tops Revenue Estimates

Shares of ShockWave Medical (NASDAQ:SWAV) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 6.12% year over year to ($0.46), which missed the estimate of ($0.42).

Recap: ShockWave Medical Q4 Earnings

SANTA CLARA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2020.

Shockwave Medical Reports Fourth Quarter and Full Year 2020 Financial Results

SANTA CLARA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 17, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

Fast Retailing Co Ltd

Freshpet

Panasonic Holdings Corp

CarParts.com, Inc.

With so much hype baked into the market, smart speculators may want to consider these under-the-radar breakout stocks for 2021. The post 7 Under-the-Radar Breakout Stocks for 2021 appeared first on InvestorPlace.

7 Under-the-Radar Breakout Stocks for 2021

Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting

Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee

Smid-cap MedTech company ShockWave Medical Inc (NASDAQ: SWAV) has seen its shares appreciate over 120% year-to-date. The ShockWave Analyst: BofA Securities analyst Bob Hopkins downgraded ShockWave from Buy to Neutral, citing valuation.

BofA Positive On Medtech Stock ShockWave In The Long Run

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

ShockWave has key differentiators that look set to make a remedial breakthrough in peripheral vascular interventions. The CAD III and PAD III IVL studies have shown superior efficacy and safety results above current standard practices.

ShockWave Is Sending Waves Throughout The Cardiology Community

Shockwave Medical, Inc. (SWAV) CEO Douglas Godshall on Q3 2020 Results - Earnings Call Transcript

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 30.91% and 34.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Reports Q3 Loss, Tops Revenue Estimates

Shares of ShockWave Medical (NASDAQ:SWAV) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 17.39% year over year to ($0.38), which beat the estimate of ($0.55).

Recap: ShockWave Medical Q3 Earnings

SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2020.

Shockwave Medical Reports Third Quarter 2020 Financial Results

Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials

Shockwave IVL Is Superior to Angioplasty in Severely Calcified Peripheral Artery Disease

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Shockwave Medical (SWAV) to Report a Decline in Earnings: What to Look Out for

SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday, November 7 at 11:00 a.m. eastern time. Dr. William Gray, M.D., FACC, FSCAI, Chief of the Division of Cardiovascular Disease at Main Line Health, Wynnewood, PA; Co-Principal Investigator of DISRUPT PAD III will present the results of the PAD III study and then will be joined by Dr. Sarang Mangalmurti, M.D., Interventional Cardiologist and Endovascular Specialist, Bryn Mawr Hospital – Main Line, Doug Godshall, Chief Executive Officer of Shockwave and Keith Dawkins, Chief Medical Officer of Shockwave to discuss the results and answer questions from investors about the study.

Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results

SANTA CLARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the acute results from the DISRUPT PAD III randomized study have been accepted for presentation in a late-breaking session at VIVA20, being held virtually from November 6-8, 2020.

Shockwave Disrupt PAD III Results to be Presented in Late-Breaking Session at VIVA20

Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application

Shockwave IVL Meets Safety and Effectiveness Endpoints in U.S. Coronary Pivotal IDE Study

SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced updated timing for the company’s CAD III Investor Webcast Event to be held in conjunction with TCT Connect. The event will now take place at 2:30 p.m. eastern time on Thursday, October 15, 2020.

News for Shockwave Medical Stock (SWAV)